CA2286442A1 - Compositions pour augmenter la concentration de cannabinoides comme vasodilatateurs et cardioprotecteurs contre l'ischemie - Google Patents
Compositions pour augmenter la concentration de cannabinoides comme vasodilatateurs et cardioprotecteurs contre l'ischemie Download PDFInfo
- Publication number
- CA2286442A1 CA2286442A1 CA002286442A CA2286442A CA2286442A1 CA 2286442 A1 CA2286442 A1 CA 2286442A1 CA 002286442 A CA002286442 A CA 002286442A CA 2286442 A CA2286442 A CA 2286442A CA 2286442 A1 CA2286442 A1 CA 2286442A1
- Authority
- CA
- Canada
- Prior art keywords
- reperfusion
- hearts
- ischemia
- ischaemia
- receptors
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 208000028867 ischemia Diseases 0.000 title claims abstract description 111
- 229930003827 cannabinoid Natural products 0.000 title claims abstract description 48
- 239000003557 cannabinoid Substances 0.000 title claims abstract description 48
- 229940065144 cannabinoids Drugs 0.000 title claims abstract description 28
- 239000000203 mixture Substances 0.000 title claims description 5
- 229940124549 vasodilator Drugs 0.000 title abstract description 5
- 239000003071 vasodilator agent Substances 0.000 title abstract description 5
- RCRCTBLIHCHWDZ-UHFFFAOYSA-N 2-Arachidonoyl Glycerol Chemical compound CCCCCC=CCC=CCC=CCC=CCCCC(=O)OC(CO)CO RCRCTBLIHCHWDZ-UHFFFAOYSA-N 0.000 claims abstract description 94
- 229950007031 palmidrol Drugs 0.000 claims abstract description 62
- HXYVTAGFYLMHSO-UHFFFAOYSA-N palmitoyl ethanolamide Chemical compound CCCCCCCCCCCCCCCC(=O)NCCO HXYVTAGFYLMHSO-UHFFFAOYSA-N 0.000 claims abstract description 62
- 230000001681 protective effect Effects 0.000 claims abstract description 20
- 239000002621 endocannabinoid Substances 0.000 claims abstract description 12
- 239000000556 agonist Substances 0.000 claims abstract description 8
- 150000001875 compounds Chemical class 0.000 claims description 19
- 238000000034 method Methods 0.000 claims description 11
- 230000003247 decreasing effect Effects 0.000 claims description 6
- 210000004027 cell Anatomy 0.000 claims description 5
- 210000002889 endothelial cell Anatomy 0.000 claims description 4
- 230000015572 biosynthetic process Effects 0.000 claims description 3
- 210000004413 cardiac myocyte Anatomy 0.000 claims description 3
- 230000015556 catabolic process Effects 0.000 claims description 3
- 230000006378 damage Effects 0.000 claims description 3
- 238000006731 degradation reaction Methods 0.000 claims description 3
- 239000002207 metabolite Substances 0.000 claims description 3
- 238000003786 synthesis reaction Methods 0.000 claims description 3
- 210000000107 myocyte Anatomy 0.000 claims description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 abstract description 79
- 230000002530 ischemic preconditioning effect Effects 0.000 abstract description 47
- 230000010410 reperfusion Effects 0.000 abstract description 47
- 230000010412 perfusion Effects 0.000 abstract description 44
- 230000024883 vasodilation Effects 0.000 abstract description 38
- 206010047141 Vasodilatation Diseases 0.000 abstract description 37
- LGEQQWMQCRIYKG-DOFZRALJSA-N anandamide Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)NCCO LGEQQWMQCRIYKG-DOFZRALJSA-N 0.000 abstract description 34
- LGEQQWMQCRIYKG-UHFFFAOYSA-N arachidonic acid ethanolamide Natural products CCCCCC=CCC=CCC=CCC=CCCCC(=O)NCCO LGEQQWMQCRIYKG-UHFFFAOYSA-N 0.000 abstract description 34
- 230000000694 effects Effects 0.000 abstract description 33
- 230000000302 ischemic effect Effects 0.000 abstract description 32
- JZCPYUJPEARBJL-UHFFFAOYSA-N rimonabant Chemical compound CC=1C(C(=O)NN2CCCCC2)=NN(C=2C(=CC(Cl)=CC=2)Cl)C=1C1=CC=C(Cl)C=C1 JZCPYUJPEARBJL-UHFFFAOYSA-N 0.000 abstract description 28
- 229960003015 rimonabant Drugs 0.000 abstract description 28
- 102000009135 CB2 Cannabinoid Receptor Human genes 0.000 abstract description 27
- 108010073376 CB2 Cannabinoid Receptor Proteins 0.000 abstract description 27
- 239000005557 antagonist Substances 0.000 abstract description 27
- XEYBHCRIKKKOSS-UHFFFAOYSA-N disodium;azanylidyneoxidanium;iron(2+);pentacyanide Chemical compound [Na+].[Na+].[Fe+2].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].[O+]#N XEYBHCRIKKKOSS-UHFFFAOYSA-N 0.000 abstract description 23
- 229940083618 sodium nitroprusside Drugs 0.000 abstract description 23
- 230000004224 protection Effects 0.000 abstract description 19
- 229940079593 drug Drugs 0.000 abstract description 17
- 239000003814 drug Substances 0.000 abstract description 17
- 230000002939 deleterious effect Effects 0.000 abstract description 15
- 230000004913 activation Effects 0.000 abstract description 14
- 210000003038 endothelium Anatomy 0.000 abstract description 14
- 230000008753 endothelial function Effects 0.000 abstract description 11
- 210000004351 coronary vessel Anatomy 0.000 abstract description 9
- 102100036214 Cannabinoid receptor 2 Human genes 0.000 abstract description 8
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 abstract description 8
- 230000002045 lasting effect Effects 0.000 abstract description 8
- 102000018208 Cannabinoid Receptor Human genes 0.000 abstract description 5
- 108050007331 Cannabinoid receptor Proteins 0.000 abstract description 5
- 230000002093 peripheral effect Effects 0.000 abstract description 5
- 229940076279 serotonin Drugs 0.000 abstract description 5
- 239000002126 C01EB10 - Adenosine Substances 0.000 abstract description 4
- 229960005305 adenosine Drugs 0.000 abstract description 4
- 230000001419 dependent effect Effects 0.000 abstract description 4
- 230000003292 diminished effect Effects 0.000 abstract description 4
- 210000004556 brain Anatomy 0.000 abstract description 3
- 230000003389 potentiating effect Effects 0.000 abstract description 2
- 230000004044 response Effects 0.000 abstract description 2
- 102000009132 CB1 Cannabinoid Receptor Human genes 0.000 abstract 3
- 108010073366 CB1 Cannabinoid Receptor Proteins 0.000 abstract 3
- 229940124802 CB1 antagonist Drugs 0.000 abstract 1
- 101710134516 Des-Arg9-bradykinin Proteins 0.000 abstract 1
- VCEHWDBVPZFHAG-POFDKVPJSA-N [des-Arg(9)]-bradykinin Chemical compound NC(N)=NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(O)=O)CCC1 VCEHWDBVPZFHAG-POFDKVPJSA-N 0.000 abstract 1
- 230000002253 anti-ischaemic effect Effects 0.000 abstract 1
- 230000007123 defense Effects 0.000 abstract 1
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 abstract 1
- 229960002986 dinoprostone Drugs 0.000 abstract 1
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 description 21
- 108020003175 receptors Proteins 0.000 description 21
- 238000001802 infusion Methods 0.000 description 19
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 12
- 230000035487 diastolic blood pressure Effects 0.000 description 12
- 230000006641 stabilisation Effects 0.000 description 12
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 11
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 11
- REOYOKXLUFHOBV-UHFFFAOYSA-N 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-n-piperidin-1-ylpyrazole-3-carboxamide;hydron;chloride Chemical compound Cl.CC=1C(C(=O)NN2CCCCC2)=NN(C=2C(=CC(Cl)=CC=2)Cl)C=1C1=CC=C(Cl)C=C1 REOYOKXLUFHOBV-UHFFFAOYSA-N 0.000 description 10
- 102000004420 Creatine Kinase Human genes 0.000 description 10
- 108010042126 Creatine kinase Proteins 0.000 description 10
- 239000012839 Krebs-Henseleit buffer Substances 0.000 description 10
- 206010062575 Muscle contracture Diseases 0.000 description 10
- 241000700159 Rattus Species 0.000 description 10
- 208000006111 contracture Diseases 0.000 description 10
- 230000002107 myocardial effect Effects 0.000 description 9
- 238000011282 treatment Methods 0.000 description 9
- 208000024172 Cardiovascular disease Diseases 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 230000005961 cardioprotection Effects 0.000 description 8
- 210000004165 myocardium Anatomy 0.000 description 8
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 7
- 206010047139 Vasoconstriction Diseases 0.000 description 7
- 229960001760 dimethyl sulfoxide Drugs 0.000 description 7
- 208000010125 myocardial infarction Diseases 0.000 description 7
- 230000025033 vasoconstriction Effects 0.000 description 7
- 108090000315 Protein Kinase C Proteins 0.000 description 6
- 102000003923 Protein Kinase C Human genes 0.000 description 6
- 230000008859 change Effects 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 238000011084 recovery Methods 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 230000003511 endothelial effect Effects 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 5
- 230000036961 partial effect Effects 0.000 description 5
- 229940044551 receptor antagonist Drugs 0.000 description 5
- 239000002464 receptor antagonist Substances 0.000 description 5
- 244000025254 Cannabis sativa Species 0.000 description 4
- 102000016924 KATP Channels Human genes 0.000 description 4
- 108010053914 KATP Channels Proteins 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 230000003293 cardioprotective effect Effects 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 210000000987 immune system Anatomy 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 230000010016 myocardial function Effects 0.000 description 4
- 238000001543 one-way ANOVA Methods 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- 150000003180 prostaglandins Chemical class 0.000 description 4
- 239000011550 stock solution Substances 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 235000012766 Cannabis sativa ssp. sativa var. sativa Nutrition 0.000 description 3
- 235000012765 Cannabis sativa ssp. sativa var. spontanea Nutrition 0.000 description 3
- XXGMIHXASFDFSM-UHFFFAOYSA-N Delta9-tetrahydrocannabinol Natural products CCCCCc1cc2OC(C)(C)C3CCC(=CC3c2c(O)c1O)C XXGMIHXASFDFSM-UHFFFAOYSA-N 0.000 description 3
- 206010048554 Endothelial dysfunction Diseases 0.000 description 3
- CYQFCXCEBYINGO-UHFFFAOYSA-N THC Natural products C1=C(C)CCC2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3C21 CYQFCXCEBYINGO-UHFFFAOYSA-N 0.000 description 3
- 230000036592 analgesia Effects 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 239000000470 constituent Substances 0.000 description 3
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 description 3
- 230000002526 effect on cardiovascular system Effects 0.000 description 3
- 230000008694 endothelial dysfunction Effects 0.000 description 3
- 208000037906 ischaemic injury Diseases 0.000 description 3
- 230000003278 mimic effect Effects 0.000 description 3
- 230000004220 muscle function Effects 0.000 description 3
- 229940005483 opioid analgesics Drugs 0.000 description 3
- 230000036407 pain Effects 0.000 description 3
- 238000010149 post-hoc-test Methods 0.000 description 3
- 238000011321 prophylaxis Methods 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 210000002460 smooth muscle Anatomy 0.000 description 3
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 206010061216 Infarction Diseases 0.000 description 2
- 102000002397 Kinins Human genes 0.000 description 2
- 108010093008 Kinins Proteins 0.000 description 2
- 108091054455 MAP kinase family Proteins 0.000 description 2
- 102000043136 MAP kinase family Human genes 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 2
- 208000003443 Unconsciousness Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 239000001110 calcium chloride Substances 0.000 description 2
- 229910001628 calcium chloride Inorganic materials 0.000 description 2
- 235000011148 calcium chloride Nutrition 0.000 description 2
- ZTGXAWYVTLUPDT-UHFFFAOYSA-N cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CC=C(C)C1 ZTGXAWYVTLUPDT-UHFFFAOYSA-N 0.000 description 2
- 239000006274 endogenous ligand Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000005802 health problem Effects 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 230000007574 infarction Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000013222 sprague-dawley male rat Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000002861 ventricular Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- ZSCHDSYZOUKNFL-DOFZRALJSA-N (8z,11z,14z,17z)-1,2,3-trihydroxytricosa-8,11,14,17-tetraen-4-one Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)C(O)C(O)CO ZSCHDSYZOUKNFL-DOFZRALJSA-N 0.000 description 1
- RCRCTBLIHCHWDZ-DOFZRALJSA-N 2-arachidonoylglycerol Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)OC(CO)CO RCRCTBLIHCHWDZ-DOFZRALJSA-N 0.000 description 1
- -1 300nM) Chemical compound 0.000 description 1
- 229940122820 Cannabinoid receptor antagonist Drugs 0.000 description 1
- VBGLYOIFKLUMQG-UHFFFAOYSA-N Cannabinol Chemical compound C1=C(C)C=C2C3=C(O)C=C(CCCCC)C=C3OC(C)(C)C2=C1 VBGLYOIFKLUMQG-UHFFFAOYSA-N 0.000 description 1
- 108091006146 Channels Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000204795 Muraena helena Species 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 206010058156 Reperfusion arrhythmia Diseases 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- QHMBSVQNZZTUGM-UHFFFAOYSA-N Trans-Cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-UHFFFAOYSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010009 beating Methods 0.000 description 1
- 230000001964 calcium overload Effects 0.000 description 1
- 230000003185 calcium uptake Effects 0.000 description 1
- QHMBSVQNZZTUGM-ZWKOTPCHSA-N cannabidiol Chemical compound OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-ZWKOTPCHSA-N 0.000 description 1
- 229950011318 cannabidiol Drugs 0.000 description 1
- 239000003536 cannabinoid receptor antagonist Substances 0.000 description 1
- 229960003453 cannabinol Drugs 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000011461 current therapy Methods 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- PCXRACLQFPRCBB-ZWKOTPCHSA-N dihydrocannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)C)CCC(C)=C1 PCXRACLQFPRCBB-ZWKOTPCHSA-N 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 229960004242 dronabinol Drugs 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 210000005240 left ventricle Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000003450 potassium channel blocker Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 125000003259 prostaglandin group Chemical group 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000007492 two-way ANOVA Methods 0.000 description 1
- 230000001196 vasorelaxation Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/25—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids with polyoxyalkylated alcohols, e.g. esters of polyethylene glycol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA002286442A CA2286442A1 (fr) | 1999-10-15 | 1999-10-15 | Compositions pour augmenter la concentration de cannabinoides comme vasodilatateurs et cardioprotecteurs contre l'ischemie |
| PCT/CA2000/001242 WO2001028588A1 (fr) | 1999-10-15 | 2000-10-16 | Cannabinoides utilises en tant que vasodilatateurs et cardioprotecteurs contre l'ischemie |
| AU10127/01A AU1012701A (en) | 1999-10-15 | 2000-10-16 | Cannabinoids as vasodilators and cardioprotectors against ischemia |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA002286442A CA2286442A1 (fr) | 1999-10-15 | 1999-10-15 | Compositions pour augmenter la concentration de cannabinoides comme vasodilatateurs et cardioprotecteurs contre l'ischemie |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2286442A1 true CA2286442A1 (fr) | 2001-04-15 |
Family
ID=4164389
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002286442A Abandoned CA2286442A1 (fr) | 1999-10-15 | 1999-10-15 | Compositions pour augmenter la concentration de cannabinoides comme vasodilatateurs et cardioprotecteurs contre l'ischemie |
Country Status (3)
| Country | Link |
|---|---|
| AU (1) | AU1012701A (fr) |
| CA (1) | CA2286442A1 (fr) |
| WO (1) | WO2001028588A1 (fr) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102004052697A1 (de) * | 2004-10-29 | 2006-05-04 | Haehner, Thomas, Dr. | Pharmazeutische Zubereitungen zur Behandlung von Folgen des Alkoholmissbrauchs, Hepatitis, Pankreatitis, Alzheimererkrankung, Morbus Parkinson, Diabetes, toxischen Nierenerkrankungen, Reperfusionsschäden, der Arteriosklerose sowie als Antidote gegen Umweltgifte und Medikamentenintoxikation |
| KR20090064435A (ko) * | 2006-10-04 | 2009-06-18 | 뉴로키 에이/에스 | 허혈의 치료를 위한 저체온 유도제의 사용 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2692575B1 (fr) * | 1992-06-23 | 1995-06-30 | Sanofi Elf | Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant. |
| WO1999026612A1 (fr) * | 1997-11-21 | 1999-06-03 | Smithkline Beecham Corporation | Nouveaux modulateurs de recepteurs de cannabinoïdes |
-
1999
- 1999-10-15 CA CA002286442A patent/CA2286442A1/fr not_active Abandoned
-
2000
- 2000-10-16 WO PCT/CA2000/001242 patent/WO2001028588A1/fr active Application Filing
- 2000-10-16 AU AU10127/01A patent/AU1012701A/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU1012701A (en) | 2001-04-30 |
| WO2001028588A1 (fr) | 2001-04-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Tissier et al. | Pharmacological postconditioning with the phytoestrogen genistein | |
| Bouchard et al. | Contribution of endocannabinoids in the endothelial protection afforded by ischemic preconditioning in the isolated rat heart | |
| Przyklenk et al. | " Reperfusion injury" by oxygen-derived free radicals? Effect of superoxide dismutase plus catalase, given at the time of reperfusion, on myocardial infarct size, contractile function, coronary microvasculature, and regional myocardial blood flow. | |
| Chen et al. | Morphine postconditioning protects against reperfusion injury in the isolated rat hearts | |
| Arikan et al. | Lipid-based antifungal agents current status | |
| Pang et al. | Pharmacological augmentation of skin flap viability: a hypothesis to mimic the surgical delay phenomenon or a wishful thought | |
| Hori et al. | Role of oxygen-derived free radicals in myocardial edema and ischemia in coronary microvascular embolization. | |
| Vinten-Johansen | Postconditioning: a mechanical maneuver that triggers biological and molecular cardioprotective responses to reperfusion | |
| Kim et al. | Brief ischemia-reperfusion induces stunning of endothelium in canine coronary artery. | |
| Iino et al. | Effect of ellagic acid on gastric damage induced in ischemic rat stomachs following ammonia or reperfusion | |
| Bouchard et al. | Role of kinins in the endothelial protective effect of ischaemic preconditioning | |
| Wallace et al. | Reduction of gastrointestinal injury in acute endotoxic shock by flurbiprofen nitroxybutylester | |
| Chan et al. | 3, 4-Dihydroxyflavonol enhances nitric oxide bioavailability and improves vascular function after ischemia and reperfusion injury in the rat | |
| Ito et al. | Effective improvement of the cerebral vasospasm after subarachnoid hemorrhage with low-dose nitroglycerin | |
| Shahidullah et al. | Cyclic GMP, sodium nitroprusside and sodium azide reduce aqueous humour formation in the isolated arterially perfused pig eye | |
| CA2286442A1 (fr) | Compositions pour augmenter la concentration de cannabinoides comme vasodilatateurs et cardioprotecteurs contre l'ischemie | |
| GB2436255A (en) | Organ preconditioning, arrest, protection, preservation and recovery (2) | |
| Yoshimoto et al. | Effect of NXY-059 on secondary mitochondrial dysfunction after transient focal ischemia; comparison with cyclosporin A | |
| Kruuse et al. | Phosphodiesterase 5 and effects of sildenafil on cerebral arteries of man and guinea pig | |
| Atkinson et al. | Effect of chronic ANG I-converting enzyme inhibition on aging processes. III. Endothelial function of mesenteric arterial bed of rat | |
| Nakamura et al. | A novel adenosine analog, AMP579, inhibits neutrophil activation, adherence and neutrophil-mediated injury to coronary vascular endothelium | |
| Kauder et al. | Antioxidant properties of dihydropyridines in isolated rat hearts: Comparison of nisoldipine, nisoldipine enantiomers, and nifedipine | |
| Abran et al. | Mechanisms of the biphasic effects of peroxides on the retinal vasculature of newborn and adult pigs | |
| Simpson et al. | Myocardial ischemia: the potential therapeutic role of prostacyclin and its analogues | |
| Miller et al. | CI-1010 induced opening of the mitochondrial permeability transition pore precedes oxidative stress and apoptosis in SY5Y neuroblastoma cells |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Dead |